ALNY News 61.41 08/13/2014 04:30:52 Alnylam Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alnylam Pharmaceuticals (ALNY) 61.41 $ALNY

Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:40AM CDT
Alnylam Pharmaceuticals Inc.'s (ALNY) second quarter 2014 loss of 63 cents per share was wider than the Zacks Consensus Estimate of a loss of 54 cents.

Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities
Business Wire - Thu Aug 07, 3:00PM CDT
--- Reported Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, Demonstrating Statistically Significant Knockdown of Antithrombin (AT) and Increase in Thrombin Generation -

The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia
Business Wire - Thu Aug 07, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designations for ALN-AT3 as an orphan medicinal product for the treatment of hemophilia A and hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), for the treatment of hemophilia and other Rare Bleeding Disorders (RBD).

Alnylam Pharmaceuticals Down 13.8% Since SmarTrend Downtrend Call (ALNY)
Comtex SmarTrend(R) - Mon Aug 04, 9:50AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.81% as of today's recent price of $53.76.

Sanofi Beats on Q2 Earnings, View Up on Strong Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:10AM CDT
Sanofi (SNY) reported second quarter 2014 business earnings of 80 cents per American Depositary Share.

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.

Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2014 on Thursday, August 7, 2014, after the U.S. financial markets close.

Alnylam to Host Additional Events in "RNAi Roundtable" Webcast Series
Business Wire - Tue Jul 29, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online "RNAi Roundtables" that it is hosting during July and August. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

Downtrend Call Working As Alnylam Pharmaceuticals Stock Falls 13.2% (ALNY)
Comtex SmarTrend(R) - Mon Jul 28, 9:21AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.21% as of today's recent price of $54.13.

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics
Business Wire - Tue Jul 22, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/693,478. The '478 patent application includes newly allowed claims directed to compositions including those comprising a modified RNA agent linked to a biantennary or triantennary ligand. Specifically, the allowed application includes claims that broadly cover single-stranded or double-stranded, chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target. The allowance of this patent application represents a major advance in Alnylam's intellectual property (IP) estate, since GalNAc-siRNA conjugates enable potent and durable silencing of liver-expressed disease genes with subcutaneous dose administration and a wide therapeutic index. Importantly, this delivery approach is a key component of the company's execution on its "Alnylam 5x15" and broader genetic medicine product strategy.

Shares of ALNY Down 14.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 16, 9:14AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 3 weeks, Alnylam Pharmaceuticals has returned 14.81% as of today's recent price of $53.13.

What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.

Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - Tue Jul 08, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.

Growth and Dividends: Europe's Best Pharma Stock
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 07, 4:00PM CDT
This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like  Regeneron  and  Alnylam Pharmaceuticals  . It's a smart play for income investors (3.5% dividend yield)...

Alnylam to Host "RNAi Roundtable" Webcast Series
Business Wire - Mon Jul 07, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online "RNAi Roundtables" during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

Alnylam Elects Amy Schulman to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.

Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
Business Wire - Mon Jun 30, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.

Senior Notes Offerings, Study Findings, Recognitions, Accreditations, and Collaborations - Analyst Notes on Tenet, Hologic, PAREXEL, Centene and Alnylam
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp (NYSE: THC), Hologic, Inc. (NASDAQ: HOLX), PAREXEL International Corporation (NASDAQ: PRXL), Centene Corp (NYSE: CNC) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4251-100free.

Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 3.73% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 5:38PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.08 to a high of $67.49. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $65.08 on volume of 821,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 19

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 88

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 150

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 15

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 81

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Changes in Leadership Position at ibex Limited

Updated Category News Views 289

Board of Directors' Transformation at ibex Limited ibex Limited, a prominent player in global business process outsourcing, has recently made significant changes to its Board of Directors. The company announced that Gerard Kleisterlee will retire from his position after the upcoming Annual General Meeting (AGM). A Fond Farewell to Gerard Kleisterlee Gerard has been an...

Continue Reading
Umicore's Shareholding Update: Impact and Insights

Updated Category News Views 148

Investor Transparency Notification from Silchester International Investors LLP Transparency notification by Silchester International Investors LLP Umicore has recently received a significant transparency notification regarding shareholding changes from Silchester International Investors LLP. This notification falls under the legal obligations concerning major holdings as...

Continue Reading
Exploring the Future of Retail at Digital Retail Africa 2025

Updated Category News Views 212

Event Overview of Digital Retail Africa 2025 The retail landscape is experiencing significant change, and Digital Retail Africa 2025 aims to prepare businesses for the rapidly evolving challenges and opportunities that lie ahead. This influential event, scheduled for January 30, 2025, at a premier venue, will gather top industry professionals, innovators, and...

Continue Reading
Understanding the Impact of Wegovy's Medicare Negotiation

Updated Category News Views 362

Implications of Wegovy's Medicare Price Negotiation The recent announcement regarding Medicare's negotiations for prescription medications has sparked considerable interest, particularly with the inclusion of Novo Nordisk's (NYSE: NVO) groundbreaking weight-loss drug, Wegovy. This decision marks a significant moment for both healthcare providers and patients across the...

Continue Reading
Max Stock Ltd. Receives Resignation News from Deputy CEO

Updated Category News Views 289

Max Stock Ltd. Announces Resignation of Deputy CEO Max Stock Limited (TASE: MAXO) has revealed that Mr. Nir Dagan, the Company’s Deputy CEO and Head of Finance, has decided to resign after nine impactful years of service. Mr. Dagan will remain in his position until the end of the calendar year. The Company appreciates Mr. Dagan’s extensive contribution over the years,...

Continue Reading